Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options
Summary Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR‐T therapy have poor outcomes. Mu...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2023-04, Vol.201 (1), p.15-24 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 24 |
|---|---|
| container_issue | 1 |
| container_start_page | 15 |
| container_title | British journal of haematology |
| container_volume | 201 |
| creator | Del Toro‐Mijares, Raul Oluwole, Olalekan Jayani, Reena V. Kassim, Adetola A. Savani, Bipin N. Dholaria, Bhagirathbhai |
| description | Summary
Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR‐T therapy have poor outcomes. Multiple mechanisms of CAR‐T therapy failure have been proposed but management of these patients remains a challenge. As CAR‐T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR‐T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody–drug conjugates and next‐generation CAR‐T therapies may provide avenues for treatment. Here we review the available data on using these drugs after failure of CAR‐T therapy and provide a framework for the ideal sequencing of these novel agents. |
| doi_str_mv | 10.1111/bjh.18656 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2771083763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2771083763</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-a4abc327c2229ee541bb3916617ee4cd6b8a8b0a489fa7c607e6872f7bc0e4b03</originalsourceid><addsrcrecordid>eNp1kc1O3DAURi1UxAzTLngBZKmbsgj4J7ETdjCiBTRSpYquI9tzM5OREwc7UZVd993wjDwJHmZggdS78eKe8-nKH0InlJzTOBd6sz6nucjEAZpSLrKE0ZR-QlNCiEwoSfMJOg5hQwjlJKNHaMKFJIVgfIr-_QKrugBL7Dz2UHlleudHbJVfAb5-_vtkwFpsx6Zbu0ZhVfXgsVnXDfjaYNX29QraaBrooogf3ox-DV514yWeD95D20dHWQvtCkK0lvs9DH1McV1fuzZ8RoeVsgG-7N8Z-v395mF-myx-_ribXy0SwzMuEpUqbTiThjFWAGQp1ZoXVAgqAVKzFDpXuSYqzYtKSSOIBJFLVkltCKSa8Bn6tsvtvHscIPRlU4ft0aoFN4SSSUlJzqXgEf36Ad24wbfxukgVNGNSFHmkznaU8S6E-Itl5-tG-bGkpNw2VMaGyteGInu6Txx0A8t38q2SCFzsgD-1hfH_SeX1_e0u8gV0HJ49</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791527698</pqid></control><display><type>article</type><title>Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options</title><source>MEDLINE</source><source>Wiley Online Library</source><source>Wiley Online Library All Journals</source><creator>Del Toro‐Mijares, Raul ; Oluwole, Olalekan ; Jayani, Reena V. ; Kassim, Adetola A. ; Savani, Bipin N. ; Dholaria, Bhagirathbhai</creator><creatorcontrib>Del Toro‐Mijares, Raul ; Oluwole, Olalekan ; Jayani, Reena V. ; Kassim, Adetola A. ; Savani, Bipin N. ; Dholaria, Bhagirathbhai</creatorcontrib><description>Summary
Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR‐T therapy have poor outcomes. Multiple mechanisms of CAR‐T therapy failure have been proposed but management of these patients remains a challenge. As CAR‐T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR‐T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody–drug conjugates and next‐generation CAR‐T therapies may provide avenues for treatment. Here we review the available data on using these drugs after failure of CAR‐T therapy and provide a framework for the ideal sequencing of these novel agents.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18656</identifier><identifier>PMID: 36709623</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Antigens, CD19 ; B-cell lymphoma ; Bispecific antibodies ; bispecific monoclonal antibodies ; Cell therapy ; Cell- and Tissue-Based Therapy ; chimeric antigen receptor T‐cell therapy ; Chimeric antigen receptors ; Clinical trials ; diffuse large B cell ; Hematology ; Humans ; Immunotherapy ; Immunotherapy, Adoptive - adverse effects ; lymphoma ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Neoplasm Recurrence, Local - etiology ; Receptors, Antigen, T-Cell - therapeutic use ; Receptors, Chimeric Antigen - therapeutic use ; relapse ; Remission</subject><ispartof>British journal of haematology, 2023-04, Vol.201 (1), p.15-24</ispartof><rights>2023 British Society for Haematology and John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-a4abc327c2229ee541bb3916617ee4cd6b8a8b0a489fa7c607e6872f7bc0e4b03</citedby><cites>FETCH-LOGICAL-c3536-a4abc327c2229ee541bb3916617ee4cd6b8a8b0a489fa7c607e6872f7bc0e4b03</cites><orcidid>0000-0003-2371-3655</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.18656$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.18656$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46388,46812</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36709623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Del Toro‐Mijares, Raul</creatorcontrib><creatorcontrib>Oluwole, Olalekan</creatorcontrib><creatorcontrib>Jayani, Reena V.</creatorcontrib><creatorcontrib>Kassim, Adetola A.</creatorcontrib><creatorcontrib>Savani, Bipin N.</creatorcontrib><creatorcontrib>Dholaria, Bhagirathbhai</creatorcontrib><title>Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR‐T therapy have poor outcomes. Multiple mechanisms of CAR‐T therapy failure have been proposed but management of these patients remains a challenge. As CAR‐T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR‐T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody–drug conjugates and next‐generation CAR‐T therapies may provide avenues for treatment. Here we review the available data on using these drugs after failure of CAR‐T therapy and provide a framework for the ideal sequencing of these novel agents.</description><subject>Antigens, CD19</subject><subject>B-cell lymphoma</subject><subject>Bispecific antibodies</subject><subject>bispecific monoclonal antibodies</subject><subject>Cell therapy</subject><subject>Cell- and Tissue-Based Therapy</subject><subject>chimeric antigen receptor T‐cell therapy</subject><subject>Chimeric antigen receptors</subject><subject>Clinical trials</subject><subject>diffuse large B cell</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Neoplasm Recurrence, Local - etiology</subject><subject>Receptors, Antigen, T-Cell - therapeutic use</subject><subject>Receptors, Chimeric Antigen - therapeutic use</subject><subject>relapse</subject><subject>Remission</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1O3DAURi1UxAzTLngBZKmbsgj4J7ETdjCiBTRSpYquI9tzM5OREwc7UZVd993wjDwJHmZggdS78eKe8-nKH0InlJzTOBd6sz6nucjEAZpSLrKE0ZR-QlNCiEwoSfMJOg5hQwjlJKNHaMKFJIVgfIr-_QKrugBL7Dz2UHlleudHbJVfAb5-_vtkwFpsx6Zbu0ZhVfXgsVnXDfjaYNX29QraaBrooogf3ox-DV514yWeD95D20dHWQvtCkK0lvs9DH1McV1fuzZ8RoeVsgG-7N8Z-v395mF-myx-_ribXy0SwzMuEpUqbTiThjFWAGQp1ZoXVAgqAVKzFDpXuSYqzYtKSSOIBJFLVkltCKSa8Bn6tsvtvHscIPRlU4ft0aoFN4SSSUlJzqXgEf36Ad24wbfxukgVNGNSFHmkznaU8S6E-Itl5-tG-bGkpNw2VMaGyteGInu6Txx0A8t38q2SCFzsgD-1hfH_SeX1_e0u8gV0HJ49</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Del Toro‐Mijares, Raul</creator><creator>Oluwole, Olalekan</creator><creator>Jayani, Reena V.</creator><creator>Kassim, Adetola A.</creator><creator>Savani, Bipin N.</creator><creator>Dholaria, Bhagirathbhai</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2371-3655</orcidid></search><sort><creationdate>202304</creationdate><title>Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options</title><author>Del Toro‐Mijares, Raul ; Oluwole, Olalekan ; Jayani, Reena V. ; Kassim, Adetola A. ; Savani, Bipin N. ; Dholaria, Bhagirathbhai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-a4abc327c2229ee541bb3916617ee4cd6b8a8b0a489fa7c607e6872f7bc0e4b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antigens, CD19</topic><topic>B-cell lymphoma</topic><topic>Bispecific antibodies</topic><topic>bispecific monoclonal antibodies</topic><topic>Cell therapy</topic><topic>Cell- and Tissue-Based Therapy</topic><topic>chimeric antigen receptor T‐cell therapy</topic><topic>Chimeric antigen receptors</topic><topic>Clinical trials</topic><topic>diffuse large B cell</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Neoplasm Recurrence, Local - etiology</topic><topic>Receptors, Antigen, T-Cell - therapeutic use</topic><topic>Receptors, Chimeric Antigen - therapeutic use</topic><topic>relapse</topic><topic>Remission</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Del Toro‐Mijares, Raul</creatorcontrib><creatorcontrib>Oluwole, Olalekan</creatorcontrib><creatorcontrib>Jayani, Reena V.</creatorcontrib><creatorcontrib>Kassim, Adetola A.</creatorcontrib><creatorcontrib>Savani, Bipin N.</creatorcontrib><creatorcontrib>Dholaria, Bhagirathbhai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Del Toro‐Mijares, Raul</au><au>Oluwole, Olalekan</au><au>Jayani, Reena V.</au><au>Kassim, Adetola A.</au><au>Savani, Bipin N.</au><au>Dholaria, Bhagirathbhai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2023-04</date><risdate>2023</risdate><volume>201</volume><issue>1</issue><spage>15</spage><epage>24</epage><pages>15-24</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR‐T therapy have poor outcomes. Multiple mechanisms of CAR‐T therapy failure have been proposed but management of these patients remains a challenge. As CAR‐T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR‐T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody–drug conjugates and next‐generation CAR‐T therapies may provide avenues for treatment. Here we review the available data on using these drugs after failure of CAR‐T therapy and provide a framework for the ideal sequencing of these novel agents.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>36709623</pmid><doi>10.1111/bjh.18656</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2371-3655</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2023-04, Vol.201 (1), p.15-24 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2771083763 |
| source | MEDLINE; Wiley Online Library; Wiley Online Library All Journals |
| subjects | Antigens, CD19 B-cell lymphoma Bispecific antibodies bispecific monoclonal antibodies Cell therapy Cell- and Tissue-Based Therapy chimeric antigen receptor T‐cell therapy Chimeric antigen receptors Clinical trials diffuse large B cell Hematology Humans Immunotherapy Immunotherapy, Adoptive - adverse effects lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Neoplasm Recurrence, Local - etiology Receptors, Antigen, T-Cell - therapeutic use Receptors, Chimeric Antigen - therapeutic use relapse Remission |
| title | Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A19%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relapsed%20or%20refractory%20large%20B%E2%80%90cell%20lymphoma%20after%20chimeric%20antigen%20receptor%20T%E2%80%90cell%20therapy:%20Current%20challenges%20and%20therapeutic%20options&rft.jtitle=British%20journal%20of%20haematology&rft.au=Del%20Toro%E2%80%90Mijares,%20Raul&rft.date=2023-04&rft.volume=201&rft.issue=1&rft.spage=15&rft.epage=24&rft.pages=15-24&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18656&rft_dat=%3Cproquest_cross%3E2771083763%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2791527698&rft_id=info:pmid/36709623&rfr_iscdi=true |